Biocon Ltd. NSE: BIOCON | BSE: 532523

Strong Performer, Getting Expensive

Download real time

395.85 5.10 (1.31%)

36.03% Gain from 52W Low

4.4M

NSE+BSE Volume

NSE 25 Feb, 2026 3:49 PM (IST)

US FDA Approval

Biocon gets US FDA nod for its Liraglutide injection, with a market size of $127 mn in 2025 See details

Biocon News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news and updates on Biocon from all sources in a single place.

Is Biocon Ltd. worth buying?

736 Votes:

Buy 74.73%

Sell 16.44%

Hold 8.83%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf